<DOC>
	<DOCNO>NCT00598013</DOCNO>
	<brief_summary>The aim study evaluate effect pioglitazone treatment insulin secretion , insulin resistance , progression atherosclerosis renal allograft recipient without preoperative history diabetes .</brief_summary>
	<brief_title>Effect Pioglitazone Insulin Resistance Atherosclerosis Renal Allograft Recipients Without Diabetes</brief_title>
	<detailed_description>This prospective , randomize , open-label study . The pioglitazone treatment group receive 30mg pioglitazone 2 week renal transplantation 12 month . After treatment , estimate insulin sensitivity index transplantation , first phase second phase insulin secretion , secretion area curve , carotid intima-media thickness .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Renal allograft recipient eligible participate study age â‰¥ 18 year , previous history organ transplantation currently use steroid immunosuppressant . Diabetes transplantation Severe metabolic infectious disease Hepatic disease Congestive heart failure ( New York Heart Association IIIV ) Cadaver donor kidney donor transplantation Unstable condition transplant kidney</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>